

Special Issue

Technologies and Methods for Studying Epitranscriptomes

Message from the Guest Editor

Many major breakthroughs in biomedical research were preceded by the development of new technologies or methodologies. To propel our studies forward and enhance our knowledge of epitranscriptomes, new technologies and methods for studying epitranscriptomes are essential. In this Special Issue, we welcome the submission of perspectives, review articles, full research reports, and technical notes with a focus on the modifications of RNA in either human or model organisms. The development, validation, and/or applications of new or improved technologies or methods that can be used in areas including but not limited to the following will be considered:

- Comprehensive profiling of epitranscriptomes;
- Sequencing or mapping RNA modifications;
- Structural studies on the effects of RNA modifications;
- Functional studies of RNA modifications;
- Multi-omics studies;
- Analysis of RNA modifications that can improve specificity, sensitivity, and/or throughput;
- Computational programs and analytics for mining the functions and distributions of RNA modifications.

Guest Editor

Prof. Dr. Norman Chiu

Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, USA

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/169591

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).